semaj83/ctmatch_classification huggingface dataset:
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Volunteers Healthy male and/or female literate subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests) Body Mass Index (BMI) of 17.5 to 26.4 kg/m2; and a total body weight >50 kg (110 lbs)  Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) A positive urine drug screen
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Functional Dyspepsia Gastric Emptying Gastric Accommodation All adult male or non-pregnant female patients who are diagnosed as functional dyspepsia and fulfilling Rome III (1) will be considered Patients should be negative for H. pylori on gastric biopsy and Urea Breath Test duodenal biopsy in these patients should be negative for giardiasis or celiac disease or any other established organic pathology A normal upper abdominal ultrasound Willing to participate and give consent for participation in the study  Age <18 years Helicobacter Pylori positive on gastric biopsy and / or UBT Taking other medications that alter gastric motility like macrolide anti-emetics and antibiotics  Pregnant or breast-feeding females
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Cholera Diarrhoea Vibrio Infection Healthy, non-pregnant adults aged 18 years and above and healthy children aged 1 will be recruited in Kolkata Males or non-pregnant females aged 18 years and above and children aged 1 -17 years who the investigator believes will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection) Written informed consent obtained from the subjects or their parents/guardians, and written assent for children aged 12 years Healthy subjects as determined by Medical history Physical examination Clinical judgment of the investigator  Ongoing serious chronic disease For females of reproductive age: Pregnancy (or females planning to become pregnant during the study period; as determined by verbal screening) Immunocompromising condition or therapy (for corticosteroids this would mean ≥0.5 mg/kg/day) Diarrhea (3 or more loose/watery stools within a 24-hour period) 6 weeks prior to enrollment One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months Intake of any anti-diarrhea medicine in the past week Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC warrants deferral of the vaccination pending recovery of the subject Receipt of immunoglobulin or any blood product during the past 3 months
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peritonsillar Abscess referring doctor suspects peritonsillar abscess patient is voluntary patient has daily access to his/her e-mail patient speaks and understands Finnish of Swedish female patients have adequate birth-control method patient has peritonsillar abscess  allergy to penicillin allergy to metronidazole use of metronidazole in preceding one month pregnancy breast-feeding renal insufficiency liver insufficiency alcoholism (drunk at least once a week) participant in another clinical trial at the moment treatment of peritonsillar abscess requires in-patient care
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Focal Nodular Hyperplasia of Liver Toxic Liver Disease With Focal Nodular Hyperplasia Liver Metastases patients diagnosed with de novo FLL at standard ultrasound age > 18 years, male and female gender informed consent for the contrast enhanced study  patients with contraindication for contrast enhanced study: subjects with acute cardiac infarction, with class III/IV cardiac insufficiency, with rhythm disorders and pregnant women Patients diagnosed with simple cysts at standard ultrasound (biliary of hydatid) Patients with known FLL, for example after percutaneous treatment, in which the contrast study is used for the follow up of the patient
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 0.0-99.0,  Cystic Fibrosis Exocrine Pancreatic Insufficiency Pancreatic Diseases Digestive System Diseases Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency due to cystic fibrosis  Patients with a history of hypersensitivity to the ingredient of LipaCreon Patients with a history of hypersensitivity to porcine protein
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Healthy Provision of signed and dated, written informed consent prior to any study-specific procedures Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture; female subjects must be post menopausal or surgically sterile Male subjects should be willing to use barrier contraception ie, condoms, from the first day of the investigational product administration until 3 months after the last administration of the investigational product Have a body mass index (BMI) between 19 and 30 kg/m2 Be able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator  History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs Known history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to carbapenem or cephalosporin antibiotics or other beta-actam antibiotics or any other investigational product to be administered as part of the study Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks prior to the first administration of investigational product Any clinically significant abnormalities in physical examination, ECG, clinical chemistry, haematology, or urinalysis results, as judged by the Investigator
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Associated Diarrhea Male and female patients 18 years of age or older Mild to moderate C.difficile associated diarrhea (CDAD) with a positive stool C.difficile toxin (by ELISA) Either a first episode of CDAD or a first recurrence (patients with more than 1 recurrence are not eligible) Greater than 3 watery or unformed bowel movements in the prior 24 hours Females of child bearing potential having a negative pregnancy test and taking adequate birth control measures Patients should not consume alcohol at least 12 hours prior to dosing (i.e. in-house monitoring) and until 48 hours after the last dose of drug administration (until Day 14) Able to comprehend and give informed consent for the study and able to adhere to study schedules and protocol requirements  Known prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives Life expectancy ≤ 60 days Sepsis, severe sepsis, or septic shock Signs or symptoms of peritonitis, megacolon or ileus History of ulcerative colitis or Crohn's disease Oral or parenteral antibiotic therapy with metronidazole or vancomycin or other drugs effective in treating DCAD (e.g., bacitracin, fusidic acid) within the 1 week prior to enrollment Recent history of significant drug or alcohol abuse within 1 year Any findings on physical examination, medical history, 12-lead ECG or clinical laboratory tests which, in the judgment of the Principal Investigator, would patients from participating in the study Patients with history of blood dyscrasias, porphyria and active non-infectious disease of the central nervous system Patients with history of rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 0.0-63.0,  Malnutrition Diarrhea Child Development (1) Infants (target child) will be eligible to participate in the study if they are They are in utero at the baseline survey Their parents/guardians are planning to stay in the study village for the next 12 months (if a mother is planning to give birth at her natal home and then return, she will still be a candidate for enrollment) (2) Children < 36 months old at baseline that are living in the compound of a target child will be eligible to participate in diarrhea measurement if They are < 36 months old at the baseline survey Their parents/guardians are planning to stay in the study village for the next 12 months (3) Children 18 months old at baseline that are living in the compound of a target child will be eligible to participate in intestinal parasite specimen collection if They are 18 months old at the baseline survey
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Acute Bacterial Infections Acute Viral Infections current acute infection age 18-70 male or female any race currently active symptoms
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Malnutrition Diarrhea Child Development Study Population Description The subject population will be young children and their mothers/guardians living in several contiguous districts of Western Province, in the rural areas outside the towns of Bungoma and Kakamega. Communities must meet the following Located in a rural area (defined as villages with <25% residents living in rental houses, <2 gas/petrol stations and <10 shops) Not enrolled in ongoing WASH or nutrition programs No chlorine dispensers at water sources installed by programs separate from the present study Majority (>80%) of households do not have access to piped water into the home At least six eligible pregnant women in the cluster at baseline From enrolled communities, household compounds will be enrolled if they meet the following criteria One or more women who self-identify as pregnant at the time of the baseline survey The woman plans to stay in the community for the next 12 months  (1) The study excludes households who do not own their home to help mitigate attrition during follow-up
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Newly Diagnosed High-Grade Glioma Patients must have histologically confirmed newly diagnosed high-grade glioma(WHO Grade III or IV) Age ≥18 years Karnofsky Performance Score (KPS) ≥ 60% Life expectancy greater than 12 weeks Patients must have adequate organ and marrow function Completed >80% of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade 3 or 4 hematologic toxicity Patients may have received Gliadel during surgery Ability to swallow pills and keep medication record women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation Ability to understand and willingness to sign a written informed consent document  Patients must not have received prior therapy other than standard chemoradiation according to Stupp et al and Gliadel Patients may not be receiving any other investigational agents while on study Patients who have known allergy to mebendazole or benzimidazole Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting mebendazole therapy Patients who have taken any benzimidazole (ABZ, flubendazole, thiabendazole, fenbendazole, triclabendazole, etc.) within the last 3 months Patients who are taking any anti-convulsant medication that interferes with the cytochrome P450 pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic hepatitis, acute hepatitis, or psychiatric illness/social situation that would limit compliance with study requirements Pregnant women are excluded Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fecal Incontinence age ≥18 years living in the community (not a nursing home or assisted living facility) self-report of usually having FI of loose or liquid consistency at least twice in a 2-wk period toilets independently ability to read and write in English Persons that regularly performed pelvic floor muscle exercises and/or biofeedback on a maintenance regimen for at least 20 wks or who took a steady dose of anti-motility medications on a regular schedule that still met the FI were also eligible  difficulty swallowing a gastrointestinal (GI) tract altered by surgery a malabsorption disorder inflammatory bowel disease gastrointestinal cancer or active cancer treatment allergy to the fibers regularly used a laxative or enema, were tube-fed, or unwilling to discontinue taking periodic self-prescribed fiber supplements or anti-diarrheal medications a score ≤24 on the Mini Mental State Examination having/reporting fewer than two episodes of FI or being incapable of performing study procedures during the run-in baseline period
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liver Transplant Rejection Patients of both sexes aged ≥ 18 years Standard analytical parameters, defined by Leukocytes ≥ 3000 Neutrophils ≥ 1500 Platelets ≥ 100,000 Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 1.5 standard range institution creatinine ≤ 1.5 mg / dl Patients with liver space occupying lesion (LOE) that require extended hepatic resection Patient selection should be cautious, covering basically 5 types of liver damage which must be submitted prior to liver volumetry Metastatic Disease subsidiary right hepatectomy extended to segment IV  Different tumor records current disease or any disease hematologic Patients with uncontrolled hypertension Severe heart failure (NYHA IV) Patients with malignant ventricular arrhythmias or unstable angina Diagnosis of deep vein thrombosis in the previous 3 months Adjunctive therapy including hyperbaric oxygen, vasoactive substances, agents or angiogenesis inhibitors against Cox-II BMI> 40 kg/m2 Patients with alcoholic with active alcoholism Proliferative retinopathy Concomitant disease that reduces life expectancy to less than a year
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Concentration-Time Profiles in Stomach & Intestine. Healthy volunteers age: 20-35 year  Diseases Acute/chronic gastrointestinal disorders Medication use Possible pregnancy Frequent exposure to x-ray radiation during the past year HIV positive
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Apparently healthy; no medical conditions that might affect the study measurements Male or female Age between 18 and 55 years of age Body mass index (BMI) between 18.5 and 24.9 kg m-2 Suitable for MRI scanning (eg absence of metal implants, infusion pumps and pacemakers as assessed by the MRI safety questionnaire  Previous gastrointestinal surgery (excluding cholecystectomy and appendectomy) Known gastrointestinal disease Smoking History of alcohol or drug abuse Taking medication that is likely to affect gastrointestinal function Participation in night shift work the week prior to the study day. (Night work is defined as working between midnight and 6 am) Strenuous exercise greater than 10 hours per week Consumption of more than 21 units of alcohol in a typical week